Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial triple vs initial dual oral combination therapy in pulmonary arterial hypertension
2015-003438-28Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of macitentan, tadalafil and selexipag in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Pulmonary vascular resistance. Started Jan 2016; status: completed.
02
Drugs
macitentantadalafilselexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2015-003438-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003438-28.